NCT01262885View on ClinicalTrials.gov

A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 7, 2010

Primary Completion Date

August 25, 2011

Study Completion Date

August 25, 2011

Conditions
Infections, Bacterial
Interventions
DRUG

GSK2251052

500 mg tablet, dose levels detailed in Arm description

DRUG

Placebo

matching placebo tablet

Trial Locations (1)

5000

GSK Investigational Site, Adelaide

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01262885 - A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter